Company: SUPN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0001356576-25-000017
Chunk: 337

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1A
Chunk 337
---
 are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ KPMG LLP

Baltimore, Maryland

February 25, 2025 

91

Supernus Pharmaceuticals, Inc.

Consolidated Balance Sheets

(in thousands, except share and per share data) December 31, 2024December 31, 2023AssetsCurrent assetsCash and cash equivalents$69,331 $75,054 Marketable securities384,281 179,820 Accounts receivable, net142,077 144,155 Inventories, net54,293 77,408 Prepaid expenses and other current assets36,088 16,676 Total current assets686,070 493,113 Long-term marketable securities— 16,617 Property and equipment, net11,545 13,530 Intangible assets, net521,912 599,889 Goodwill117,019 117,019 Other assets31,527 37,505 Total assets$1,368,073 $1,277,673 Liabilities and stockholders’ equityCurrent liabilitiesAccounts payable and accrued liabilities$76,352 $79,569 Accrued product returns and rebates168,705 154,274 Contingent consideration, current portion47,340 52,070 Other current liabilities— 4,283 Total current liabilities292,397 290,196 Contingent consideration, long-term— 1,380 Operating lease liabilities, long-term27,382 33,196 Deferred income tax liabilities, net4,961 24,963 Other liabilities7,600 6,422 Total liabilities332,340 356,157 Commitments and contingencies (Note 16)Stockholders’ equityCommon stock, $0.001 par value; 130,000,000 shares authorized; 55,743,095 and 54,723,356